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only addressed absenteeism ± disability without regards to 
presenteeism; true productivity costs are likely even higher 
than reported. Cost assessment measures in clinical trials for
ﬁbromyalgia need to be determined.
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Brewer K1,Yang W1, Sarawate CS1, Grifﬁth C2, Bakst A2
1HealthCore, Inc, Wilmington, DE, USA; 2TAP Pharmaceuticals, Inc,
Lake Forest, IL, USA
OBJECTIVE: To develop benchmark methodology for identify-
ing gout patients and acute attacks, prevalence, patient charac-
teristics, and rate of gout attacks from MCO data. METHODS:
This retrospective study was in a 1.1 million southeastern US
MCO. Patients had ≥2 visits with ICD-9 code for gout (274.xx)
or ≥1 pharmacy script(s) for allopurinol, colchicine, probenecid,
or sulﬁnpyrazone between January 1, 2000 and December 31,
2002 (intake period). Patients on allopurinol without an ICD-9
code for gout were excluded if they had neoplasm or nephrolithi-
asis. First gout claim/script within the intake period was the
index date. Patients ≥18 years with continuous eligibility for one-
year pre and post index date were included. Gout attack was
deﬁned as ofﬁce or ER visit with medical claim for gout or joint
pain (ICD-9 719.4x) and ≥1 of the following within seven days
but not within six months prior: new pharmacy claim for
NSAID, colchicine, corticosteroid, ACTH, intra-articular aspi-
ration/injection, or microscopy of joint ﬂuid. Statistical analysis
was performed on continuous and categorical variables.
RESULTS: A study cohort of 5942 gout patients was identiﬁed
with prevalence rate of 1.6%. In this database, gout patients
were relatively older (mean age 57 ± 14 years), predominantly
male (76%), suffered from substantial cardiovascular pre-index
comorbidities (hypertension [40%], CHD [25%]), diabetes
(18%), and renal impairment (5%). Nineteen percent (1121/
5942) of patients had ≥1 gout attack. Among the gout attack
subset, median rate of attacks per patient per year was 0.57
(range 0.24 to 6.9). CONCLUSION: Patients with gout were
older, predominantly male, and had high rates of cardiovascular
comorbidities. The prevalence rate identiﬁed is similar to other
estimates in the literature. Further research is necessary to reﬁne
and validate our methodology since this work did not address
self-managed gout attacks.
ARTHRITIS—Rheumatoid Arthritis
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OBJECTIVES: To compare health care utilization and total
direct medical cost in patients with Rheumatoid arthritis (RA)
with those of the general population in a Hospital based Health
Management Organization (HMO). METHODS: A toal of 
127 RA patients (all fulﬁlling ARA criteria 1982) (111 (87%)
females, mean age 62.7 years, median disease duration: 6.7
(interquartile range: 4–11), 77% seropositive) with continuous
afﬁliation with the HMO during year 2003 were included. All
direct medical expenditures from the insurer’s point of view and
health care utilization during year 2003 were considered and
compared with mean values of the adult HMO population 
(n = 69,891), standardized by patient’s sex and age distribution.
Data was obtained from charges to the HMO and considered as
proxy to costs. Costs are expressed in 2003 American dollars.
RESULTS: RA had signiﬁcantly more mean annual hospitaliza-
tions: 0.27 (SD0 .61) vs. 0.16 (SD 0.51), p = 0.025; mean annual
medications purchased :34 (SD27) vs. 27.5 (SD 27) p = 0.01;
mean annual medical visits 19 (SD11) vs. 14.5 (SD 14) p < 0.001,
and outpatients procedures 48 (SD37) vs. 31 (SD 25); p < 0.001.
RA patients also had signiﬁcantly more mean total direct medical
costs than general population ($752 vs. $557; p = 0.006). Com-
ponents of direct medical costs were: medical visits: 13%, med-
ications: 24%, hospitalizations: 38% and outpatient procedures:
25%. Only one patient was on biologic treatment. There were
no differences in costs between seropositive and seronegative
patients, males or females or in relation to disease duration.
CONCLUSIONS: RA patients used signiﬁcantly more health
care resources and were signiﬁcantly more costly than the general
population of same age and sex. In a developing country with
scarce use of biologic therapy, direct medical costs are still mainly
driven by hospitalizations.
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OBJECTIVES: To determine rheumatologists’ current prescrib-
ing practices, laboratory monitoring protocols, and perceived
barriers to prescribing Tumor Necrosis Factor (TNF) inhibitors
(adalimumab, etanercept, and inﬂiximab) in patients with
rheumatoid arthritis (RA). METHODS: A survey questionnaire
was mailed to 1970 rheumatologists who were randomly
selected from a national sample of 3007 rheumatologists. A 
one-page nonresponse questionnaire was mailed to about 200
randomly selected nonresponding rheumatologists to assess non-
response bias. RESULTS: Two mailings yielded a response rate
of 22.2% (428 completed, usable surveys out of 1925 deliver-
able surveys). Rheumatologists reported using all three agents in
patients with moderate RA (82–87%) and severe RA (94–96%).
Also, some rheumatologists (10–18%) reported using these
agents in newly diagnosed and mild RA patients. Sixty eight
percent preferred etanercept as ﬁrst choice TNF inhibitor while
28.5% and 20.3% preferred adalimumab and inﬂiximab as ﬁrst
choice TNF inhibitors, respectively. In patients with severe RA
and an inadequate response to methotrexate, 91% rheumatolo-
gists reported using TNF inhibitor with one other disease mod-
ifying anti-rheumatic drug (DMARD) and 27.9% reported using
TNF inhibitor with two other DMARDs. Over 94% rheuma-
tologists stated switching patients from one TNF inhibitor to 
a different TNF inhibitor due to inadequate response or side
effects. Most rheumatologists ordered puriﬁed protein derivative
test (96%) when administering these agents with almost 82%
conducting this test at baseline. Other tests ordered were com-
plete blood count, chest radiography, antinuclear antibody, and
creatinine during baseline and follow-up of patients. Costs to the
patients and insurance coverage were perceived as major barri-
ers to prescribing these agents although the perception was a
little lower with inﬂiximab than with adalimumab or etanercept.
CONCLUSIONS: Rheumatologists are fairly similar in their use
of the three different TNF inhibitors although some variation
